An in  vivo safety and efficacy demonstration of a topical liposomal @entity842 donor treatment for XXXX biofilm-associated rhinosinusitis.

@entity1244 @entity32 @entity742 @entity794 @entity102 @entity842 @entity15230 @entity479
UNASSIGNED: The burden of drug resistance emerges in the wake of chronic and repeated antibiotic use. This underpins the importance of discovering alternatives to current antibiotic regimens. In @entity102 ( @entity102 ), topical therapy such as nasal douches and @entity479 sprays is the mainstay of treatment. However, @entity1244 such as those with @entity794 biofilm infection point to more recalcitrant @entity102 subtypes, focusing research efforts into topical antimicrobial therapies. In the sinuses, both local mucosal and systemic effects must be considered in designing any new topical medication. @entity842 (NO), an endogenous antimicrobial agent, is found at extremely low levels in @entity102 sinuses and high levels in healthy sinuses. As a novel treatment modality, we have designed a liposomal formulation of an NO donor (LFNO) using @entity15230 , as a topical sinus wash in a @entity742 model of @entity794 biofilm rhinosinusitis. Heart rate (HR), blood pressure, mean arterial pressure (MAP), and histologic and ciliary analyses were assessed in the safety component. Efficacy was assessed by quantifying biofilm biomass post-treatment. LFNO-treated @entity742 had lesser @entity32 (P  =  0.02), and comparable ciliary preservation (P  =  0.86) than the control group. A transient increase in HR and decrease in MAP were observed in the LFNO group (P  <  0.05), but this was not accompanied by observable side effects. LFNO @entity742 had significantly lower biofilm biomass vs controls (P  =  0.044). Our findings demonstrate the localized and systemic safety of LFNO in an animal model despite using high NO concentrations, thus warranting further investigation for its possible therapeutic role in @entity102 .
